As compared to controls, elevated nasal levels of ACE2 and TMPRSS2 were associated with a 3.6-fold increased risk of SARS-CoV ...

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).